NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,730 | -99.8% | 90 | -98.7% | 0.00% | -100.0% |
| Q2 2021 | $756,000 | -37.8% | 6,948 | -5.2% | 0.01% | -28.6% |
| Q1 2021 | $1,215,000 | -5.7% | 7,330 | +0.1% | 0.01% | -12.5% |
| Q4 2020 | $1,288,000 | +4.3% | 7,321 | -4.0% | 0.01% | -11.1% |
| Q3 2020 | $1,235,000 | +19.3% | 7,628 | -1.3% | 0.01% | +12.5% |
| Q2 2020 | $1,035,000 | +6.2% | 7,728 | -5.3% | 0.01% | -11.1% |
| Q1 2020 | $975,000 | -15.9% | 8,157 | -4.2% | 0.01% | 0.0% |
| Q4 2019 | $1,160,000 | – | 8,517 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |